Support Alert

Class 4 Medicines Defect Information (caution in use) Bleo-Kyowa, powder for solution for injection, 15,000 IU

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 4 drug alert for a specific batch of Bleo-Kyowa, Powder for Solution for Injection (Bleomycin sulfate), 15,000 IU. This is because In April 2017, glass particles were detected in a batch of Bleo-Medac (bleomycin sulfate) from the same manufacturer. 

Further details of the alert, the affected batch, and action to take are available on the MHRA website.